Heteroaryl compounds for kinase inhibition

US10227342B2 · kind B2 · utility

Assignee

• Ariad Pharmaceuticals, Inc. · US

Inventors

• Wei-Sheng Huang · Cambridge, US
• Yongjin Gong · Belmont, US
• Feng Li · Winchester, US
• Nicholas E. Bencivenga · Cambridge, US
• David C. Dalgarno · Brookline, US
• Anna Kohlmann · Winchester, US
• William C. Shakespeare · Framingham, US
• Ranny M. Thomas · Cambridge, US
• Xiaotian Zhu · Newton, US
• Angela V. West · Watertown, US
• Willmen Youngsaye · Boston, US
• Yun Zhang · Acton, US
• Tianjun Zhou · Belmont, US

Key dates

• Filing date: May 13, 2015
• Grant date: Mar 12, 2019
• Expiry date: May 13, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/65583
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.